Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Cash from Financing Activities (2019 - 2025)

IDEAYA Biosciences (IDYA) has disclosed Cash from Financing Activities for 7 consecutive years, with $2.1 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 22.63% to $2.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $29.8 million through Dec 2025, down 95.6% year-over-year, with the annual reading at $29.8 million for FY2025, 95.6% down from the prior year.
  • Cash from Financing Activities hit $2.1 million in Q4 2025 for IDEAYA Biosciences, up from $301000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $349.1 million in Q1 2024 to a low of $301000.0 in Q3 2025.
  • Historically, Cash from Financing Activities has averaged $65.6 million across 5 years, with a median of $21.1 million in 2021.
  • Biggest five-year swings in Cash from Financing Activities: soared 123441.18% in 2021 and later tumbled 99.89% in 2025.
  • Year by year, Cash from Financing Activities stood at $688000.0 in 2021, then plummeted by 52.91% to $324000.0 in 2022, then soared by 43385.8% to $140.9 million in 2023, then tumbled by 98.05% to $2.8 million in 2024, then fell by 22.63% to $2.1 million in 2025.
  • Business Quant data shows Cash from Financing Activities for IDYA at $2.1 million in Q4 2025, $301000.0 in Q3 2025, and $1.2 million in Q2 2025.